AstraZeneca (BUE:AZN) Net Income From Continuing Operations : ARS9,193,345 Mil (TTM As of Mar. 2025)

View and export this data going back to . Start your Free Trial

What is AstraZeneca Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. AstraZeneca's net income from continuing operations for the three months ended in Mar. 2025 was ARS3,626,658 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2025 was ARS9,193,345 Mil.

AstraZeneca Net Income From Continuing Operations Historical Data

The historical data trend for AstraZeneca's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Net Income From Continuing Operations Chart

AstraZeneca Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income From Continuing Operations

Get a 7-Day Free Trial

318,684.07

-26,762.35

419,292.64

2,490,539.00

8,777,910.09

AstraZeneca Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Income From Continuing Operations	Get a 7-Day Free Trial															2,359,000.04	2,146,513.47	1,737,513.92	1,682,660.02	3,626,657.66

AstraZeneca Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS9,193,345 Mil.

AstraZeneca Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (BUE:AZN) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

AZNCF:USA AZN:USA AZN:Sweden AZN1:Mexico AZNN:Mexico AZNl:UK AZN:UK ZEGA:Germany ZEG:Germany ZEG:Germany ZEG:Germany ZEGA:Germany ZEG:Germany A1ZN34:Brazil AZNA:Austria

Address

1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA

Website

https://www.astrazeneca.com

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.